Core Insights - The company reported a 2% decline in comparable sales, primarily due to significant declines in China, while showing growth in Personal Health outside of China [5][10] - Order intake increased by 2%, driven by strong performance in North America, despite challenges in the Chinese market [4][10] - The adjusted EBITA margin decreased by 80 basis points to 8.6%, influenced by lower sales, although partially offset by higher gross margins from innovations [6][10] Group and Segment Performance - Comparable order intake rose by 2%, with North America showing strong momentum, while China experienced a decline [4][10] - Group comparable sales decreased by 2%, with double-digit declines in all segments in China, but slight growth in Personal Health in other markets [5][10] - Diagnosis & Treatment sales fell by 4%, impacted by a high comparison base and declines in China, while Image-Guided Therapy maintained strong performance [7][10] Financial Performance - Income from operations increased to EUR 154 million, while free cash flow showed an outflow of EUR 1,091 million, largely due to a significant payment related to the Philips Respironics recall [6][10] - Productivity initiatives yielded savings of EUR 147 million in Q1, contributing to a target of EUR 800 million in savings for 2025 [12] Innovation and Technology - Philips was recognized as the leading applicant in medical technology at the European Patent Office in 2024, highlighting its commitment to innovation [9] - New AI technologies were introduced to enhance imaging and patient outcomes, with significant advancements in MRI and ultrasound systems [15] Outlook - The company updated its full-year 2025 outlook, factoring in the impact of announced tariffs, with an estimated net tariff impact of EUR 250-300 million [13][16] - The outlook for comparable sales growth remains unchanged at 1%-3%, with expectations for modest improvement in Q2 compared to Q1 [16]

Core Insights - The MedTech industry, particularly health technology, is facing challenges in 2025 due to rising tariffs and unstable capital markets, leading to adjusted expectations across companies [1][4] Industry Overview - The re-emergence of aggressive U.S. trade policies, including a 145% baseline tariff on Chinese imports, has significantly impacted global supply chains, particularly for medical technology companies with manufacturing ties to China and Mexico [2] - Health tech startups are experiencing more difficulties compared to larger companies, facing production delays, higher costs, and tighter access to funding, which may hinder innovation in key areas [4][12] Company Performance - GE Healthcare reported a 3% increase in first-quarter revenues and a 51% surge in net income, but reduced its full-year adjusted EPS forecast due to an 85 cents per share tariff impact [5] - Johnson & Johnson disclosed a $400 million tariff burden affecting its medical device exports to China, while also announcing a $55 billion domestic investment plan [6][7] - Abbott achieved a 4% revenue increase and 8.2% growth in net earnings in Q1, but anticipates a significant tariff impact, although it maintained its earnings forecast [8][9] - Boston Scientific's first-quarter adjusted EPS rose by 33.9% with a 20.9% revenue growth, and the company raised its 2025 guidance despite expecting a $200 million tariff hit [10][11] Startup Challenges - U.S. digital health funding rose to $3 billion in Q1 2025, but remains below the $6.6 billion peak in 2021, indicating a cautious investment environment for startups [12] - Startups like Reperio Health are facing pressures from tariffs and supply chain issues, while others like Float Health are focusing on cost-cutting and improving patient access [12][13] Future Outlook - Most MedTech companies are preparing for a future with persistent trade barriers, emphasizing the need for supply chain diversification and U.S. manufacturing investments [14]

Core Viewpoint - Cuprina Holdings has completed the construction of an in-vitro fertilization (IVF) media production facility in Singapore, obtaining ISO 13485 certification and a dealer license, aiming to produce 14 SKUs of IVF media products by the fourth quarter of 2026 [1][2][4]. Company Overview - Cuprina Holdings is a biomedical and biotechnology company focused on developing products for chronic wound management, infertility, and cosmeceuticals [8]. - The company has experience in establishing ISO 13485-compliant facilities, which enhances its capability to manage production effectively [7]. Facility and Collaboration - The IVF media production facility was built in collaboration with Ferti-Craft Pte Ltd., a Singapore-based medtech company [3]. - The facility will produce IVF media products containing essential nutrients and materials for in-vitro fertilization [3]. - Ferti-Craft will handle regulatory documentation and logistics for raw materials, contributing expertise in assisted reproductive technology [5]. Regulatory and Market Outlook - The facility aims to secure regulatory approval from the Singapore Health Sciences Authority (HSA) for commercial sale of the IVF media products by late 2026 [4][6]. - The global Assisted Reproductive Technology (ART) market was valued at $34.7 billion in 2023 and is projected to grow at a CAGR of 6.9%, reaching $62.8 billion by 2032 due to increasing infertility rates and acceptance of ART [7].

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was approximately $383 million, reflecting a reported growth of 3.7% but an organic decline of 3.5% primarily due to ship holds [7][23][24] - Adjusted EPS for the quarter was $0.41, down 25% compared to 2024 [8][24] - Gross margins were 52.2%, down 220 basis points from 2024, impacted by manufacturing variances and increased network optimization spend [24] - Adjusted EBITDA margins were 16.6%, down 290 basis points compared to 2024 [24] Business Line Data and Key Metrics Changes - Codman Specialty Surgical (CSS) segment reported revenues of $281 million, with a reported growth of 9.4% but an organic decline of 1.1% [25] - Tissue Technologies revenues were $102 million, down approximately 9% on both a reported and organic basis [28] - The ENT business saw approximately $29 million in revenue from the Aclaren acquisition, while organic growth was flat due to supply constraints [26] Market Data and Key Metrics Changes - Global neurosurgery revenues declined 4.7% organically, largely due to ship holds affecting several product lines [25] - International performance within CSS declined by high single digits, primarily due to the timing and duration of ship holds [27] Company Strategy and Development Direction - The company is focused on a turnaround strategy that includes portfolio prioritization and disciplined program management to enhance operational execution [10][11] - A compliance master plan is in place to address quality system regulations and FDA observations, with significant progress reported in site assessments [12][14] - Investments are being made in operational excellence, including the Braintree facility to restart production of key products [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the specialized product portfolio despite current challenges [9] - The anticipated revenue headwinds from ship holds are within the assumptions made when setting guidance ranges [20] - The company expects second quarter revenue to be in the range of $390 million to $400 million, reflecting a reported decline of approximately 6.8% to 4.4% [19][35] Other Important Information - The company identified additional ship holds for certain products, now expecting total ship holds for the year to be between $55 million and $70 million [13][36] - The impact of recently announced global tariffs has been incorporated into the updated 2025 guidance, estimated at approximately $22 million [21][33] Q&A Session Summary Question: Clarification on Q2 guidance and shipment delays - Management acknowledged that the Q2 guidance reflects newly identified ship holds, which impacted expectations, but they had anticipated potential disruptions as part of their compliance plan [42][44] Question: Mitigation efforts related to tariffs - Management is pursuing several mitigation strategies, including tariff exemptions and pricing adjustments, but these impacts have not been built into the current guidance [48][50] Question: Demand visibility for private label products - Management expects a step-up in private label sales in the second half of the year, although the forecast has been adjusted to reflect a low single-digit decline for the full year [54] Question: Impact of tariffs on financials - Approximately half of the estimated $22 million tariff impact is attributed to exposure in China, with the remainder from other international imports [66][86] Question: Ship hold increase and organic growth outlook - The increase in ship holds is projected to have an annual impact of $55 million to $70 million, which has been factored into the organic growth outlook [94][96]

Core Viewpoint - NeurAxis, Inc. is set to release its financial results for the first quarter of 2025 on May 12, 2025, before market open, followed by a conference call to discuss the results [1]. Financial Results Announcement - The financial results will cover the period ended March 31, 2025 [1]. - A conference call is scheduled for May 12, 2025, at 9:00 a.m. Eastern Time to review the results [1]. Conference Call Details - Interested parties can access the conference call via a live webcast available on the Company's Investor Relations website [2]. - Participants can submit questions through the webcast portal or via email [2]. - Call-in participants must register to receive dial-in information and a unique PIN [3]. Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies for chronic and debilitating conditions in both children and adults [4]. - The company is advancing its proprietary IB-Stim™ therapy, which is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 [4]. - Additional clinical trials for PENFS technology are ongoing for various pediatric and adult conditions with significant unmet healthcare needs [4].

Core Viewpoint - BioSig Technologies, Inc. has entered into a Letter of Intent to merge with Streamex Exchange Corporation in an all-stock transaction, aiming to bring a real-world asset tokenization company public on Nasdaq [1][2] Proposed Transaction Highlights - The merger will create a platform for real-world asset tokenization, focusing on commodities, enhancing investment processes, and increasing capital availability for companies and investors [5][6] - Streamex aims to revolutionize commodity finance by bringing commodity markets on-chain, leveraging advanced financial technologies and blockchain transparency [7] Company Background - Streamex is a real-world asset tokenization company targeting the commodities sector, led by experienced executives from financial, commodities, and blockchain industries [6] - The company believes in the future of finance through tokenization and decentralized markets, aiming to enhance liquidity and accessibility for investors [7] Leadership Changes - Post-merger, Henry McPhie will become the CEO, and Morgan Lekstrom will serve as Chairman of the Board, with Anthony Amato remaining on the Board [12] - Strategic advisors with significant industry experience will be added to the Board, including Frank Giustra, Mathew August, and Mitchell Williams [12] Ownership Structure - After the merger, former stockholders of Streamex will own approximately 75% of the outstanding Common Stock of the combined company, while current BioSig stakeholders will hold the remaining equity [13]

Core Insights - Integra LifeSciences Holdings Corporation reported total revenues of $382.7 million for Q1 2025, reflecting a 3.7% increase on a reported basis but a 3.5% decline on an organic basis compared to the previous year [3][13] - The company experienced a GAAP net loss of $(25.3) million, or $(0.33) per diluted share, compared to a net loss of $(3.3) million, or $(0.04) per diluted share, in Q1 2024 [5][13] - Adjusted EBITDA for Q1 2025 was $63.6 million, representing 16.6% of revenue, down from $71.8 million, or 19.5% of revenue, in the prior year [4][29] Financial Performance - Total revenues for the Codman Specialty Surgical segment were $280.7 million, showing reported growth of 9.4% but an organic decline of 1.1% compared to Q1 2024 [6] - The Tissue Technologies segment reported revenues of $102.0 million, a decline of 9.3% on a reported basis and 9.1% organically compared to the same quarter last year [7] - The company generated cash flow from operations of $(11.3) million in the quarter, with total balance sheet debt at $1.85 billion and net debt at $1.58 billion, resulting in a consolidated total leverage ratio of 4.3x [7][8] Outlook - For Q2 2025, the company expects reported revenues between $390 million and $400 million, indicating a decline of 6.8% to 4.4% on a reported basis and 7.5% to 5.1% organically [9] - The full-year 2025 revenue guidance remains at $1.650 billion to $1.715 billion, representing reported growth of 2.4% to 6.5% and organic growth of 0.4% to 4.4% [10] - Adjusted EPS guidance for 2025 has been reduced to a range of $2.19 to $2.29 per share, accounting for an estimated impact of $(0.22) per share due to new tariffs [10] Segment Insights - Sales in the Neurosurgery segment declined by 4.7% on an organic basis, attributed to shipping holds across several product lines [14] - Instruments sales grew by 15.1% on an organic basis due to strong demand and favorable prior year comparisons [14] - The ENT segment reported significant revenue growth driven by the Acclarent acquisition, while private label sales decreased by 13.3% due to component supply delays [14]

Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites. MyoVista Insights is a cloud-native next-generation ECG Management System designed to enhance ...

Core Insights - Boston Scientific Corporation will participate in two investor conferences in May 2025 [1] Group 1: Upcoming Events - On May 13, 2025, Dan Brennan and Joe Fitzgerald will engage in a 30-minute Q&A session at Bank of America's 2025 Health Care Conference starting at 8:00 a.m. PT / 11:00 a.m. ET [2] - On May 28, 2025, Mike Mahoney and Ken Stein will participate in a 50-minute Q&A session at Bernstein's 41st Annual Strategic Decisions Conference starting at 8:00 a.m. ET [3] Group 2: Webcast Information - A live webcast and replay for each event will be available at Boston Scientific's investor relations website, with the replay accessible approximately one hour after the event concludes [4] Group 3: Company Overview - Boston Scientific is a global leader in medical technology, transforming lives through innovative solutions that improve patient health and reduce healthcare costs [5]

Financial Data and Key Metrics Changes - Revenues grew 6% or 0.9% organically, which was below expectations, primarily due to market dynamics in Life Sciences and a slower return to normal levels in blood culture testing [6][12] - Adjusted gross margins increased to 54.9%, up 190 basis points year over year, driven by BD Excellence initiatives [7][26] - Adjusted diluted EPS was $3.35, reflecting a growth of 5.7% [26][30] Business Line Data and Key Metrics Changes - Biosciences faced challenges due to reduced global research funding, impacting instrument sales, while reagent sales continued to grow [9][11] - Diagnostics experienced softness in the Bactech Blood Culture business, with a slower recovery in testing levels [11][12] - Farm Systems returned to growth in Q2, driven by biologics and increased orders for GLP-1s [13][24] Market Data and Key Metrics Changes - Total company organic growth was led by the U.S., Greater Asia (excluding China), and Latin America, while EMEA declined and China saw a double-digit decrease [24] - The company adjusted its full-year revenue guidance to expect 3% to 3.5% organic growth due to market dynamics [12][29] Company Strategy and Development Direction - The company is focused on navigating the near-term environment while positioning itself for long-term value through strategic investments [6][19] - BD plans to invest $2.5 billion in U.S. manufacturing over the next five years to strengthen its position in the healthcare system [15][18] - The separation process for the Biosciences and Diagnostics business is on track, with strong interest in the assets [19][85] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns over the volatility in research funding and its impact on sales, particularly in the Life Sciences segment [6][77] - The company remains committed to mitigating tariff impacts and expects to absorb $90 million in tariff expenses for FY 2025 [17][30] - Future guidance includes total revenue growth of 7.8% to 8.3% and organic growth of 3% to 3.5% for the remainder of the fiscal year [29][30] Other Important Information - BD Excellence initiatives are seen as a key driver for margin expansion and growth investments in R&D and commercial programs [8][22] - The company is actively managing its supply chain to mitigate tariff impacts and has implemented cost containment measures [18][72] Q&A Session Summary Question: Clarification on tariff impact - The $0.25 EPS impact from tariffs is a net number after mitigation efforts, and the situation remains fluid with ongoing adjustments [33][36] Question: Expectations for organic growth in the second half - The company expects organic growth to improve sequentially, with Q3 around 3% and Q4 expected to exceed 5% due to easier comparisons and key growth drivers [39][51] Question: Breakdown of organic sales growth adjustments - The adjustment reflects known headwinds in China and market-driven factors, with significant impacts from BDB and research spending [54][56] Question: Actions regarding tariffs and mitigation - The company is employing multiple strategies, including inventory positioning and sourcing alternatives, to mitigate tariff impacts [64][66] Question: Confidence in guidance amid market changes - Management acknowledged the challenges but emphasized strong execution on earnings and the ability to navigate macro dynamics effectively [75][82] Question: Update on Life Sciences separation process - The separation remains on schedule with strong interest in the assets, and details will be shared in the summer [85][86]